151 related articles for article (PubMed ID: 38003308)
1. Adjuvant Effect of Cinnamon Polyphenolic Components in Colorectal Cancer Cell Lines.
Palmioli A; Forcella M; Oldani M; Angotti I; Sacco G; Fusi P; Airoldi C
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003308
[TBL] [Abstract][Full Text] [Related]
2. Cinnamon extract induces tumor cell death through inhibition of NFkappaB and AP1.
Kwon HK; Hwang JS; So JS; Lee CG; Sahoo A; Ryu JH; Jeon WK; Ko BS; Lee SH; Park ZY; Im SH
BMC Cancer; 2010 Jul; 10():392. PubMed ID: 20653974
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status.
Kato J; Futamura M; Kanematsu M; Gaowa S; Mori R; Tanahashi T; Matsuhashi N; Yoshida K
Int J Cancer; 2016 Mar; 138(6):1516-27. PubMed ID: 26437179
[TBL] [Abstract][Full Text] [Related]
4. FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer.
Marzi L; Combes E; Vié N; Ayrolles-Torro A; Tosi D; Desigaud D; Perez-Gracia E; Larbouret C; Montagut C; Iglesias M; Jarlier M; Denis V; Linares LK; Lam EW; Martineau P; Del Rio M; Gongora C
Br J Cancer; 2016 Nov; 115(10):1223-1233. PubMed ID: 27685445
[TBL] [Abstract][Full Text] [Related]
5. Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer.
Hu S; Dai H; Li T; Tang Y; Fu W; Yuan Q; Wang F; Lv G; Lv Y; Fan X; Zhang S; Jin R; Shen Y; Lin F; Ye X; Ding M; Yang Y; Lei C
Cancer Lett; 2016 Nov; 382(1):32-43. PubMed ID: 27569653
[TBL] [Abstract][Full Text] [Related]
6. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
[TBL] [Abstract][Full Text] [Related]
7. ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer.
Geißler AL; Geißler M; Kottmann D; Lutz L; Fichter CD; Fritsch R; Weddeling B; Makowiec F; Werner M; Lassmann S
Oncotarget; 2017 Mar; 8(10):17164-17190. PubMed ID: 28199979
[TBL] [Abstract][Full Text] [Related]
8. 3-Bromopyruvate overcomes cetuximab resistance in human colorectal cancer cells by inducing autophagy-dependent ferroptosis.
Mu M; Zhang Q; Zhao C; Li X; Chen Z; Sun X; Yu J
Cancer Gene Ther; 2023 Oct; 30(10):1414-1425. PubMed ID: 37558749
[TBL] [Abstract][Full Text] [Related]
9. Whole Transcriptome Analysis Identifies TNS4 as a Key Effector of Cetuximab and a Regulator of the Oncogenic Activity of KRAS Mutant Colorectal Cancer Cell Lines.
Kim S; Kim N; Kang K; Kim W; Won J; Cho J
Cells; 2019 Aug; 8(8):. PubMed ID: 31409052
[TBL] [Abstract][Full Text] [Related]
10. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
[TBL] [Abstract][Full Text] [Related]
11. Combinational treatment with microRNA‑133b and cetuximab has increased inhibitory effects on the growth and invasion of colorectal cancer cells by regulating EGFR.
Zhou J; Lv L; Lin C; Hu G; Guo Y; Wu M; Tian B; Li X
Mol Med Rep; 2015 Oct; 12(4):5407-14. PubMed ID: 26151111
[TBL] [Abstract][Full Text] [Related]
12. PHLDB2 Mediates Cetuximab Resistance via Interacting With EGFR in Latent Metastasis of Colorectal Cancer.
Luo M; Huang Z; Yang X; Chen Y; Jiang J; Zhang L; Zhou L; Qin S; Jin P; Fu S; Peng L; Li B; Fang Y; Pu W; Gong Y; Liu Y; Ren Z; Liu QL; Wang C; Xiao F; He D; Zhang H; Li C; Xu H; Dai L; Peng Y; Zhou ZG; Huang C; Chen HN
Cell Mol Gastroenterol Hepatol; 2022; 13(4):1223-1242. PubMed ID: 34952201
[TBL] [Abstract][Full Text] [Related]
13. HGF rescues colorectal cancer cells from EGFR inhibition via MET activation.
Liska D; Chen CT; Bachleitner-Hofmann T; Christensen JG; Weiser MR
Clin Cancer Res; 2011 Feb; 17(3):472-82. PubMed ID: 21098338
[TBL] [Abstract][Full Text] [Related]
14. Combination effect of cetuximab with radiation in colorectal cancer cells.
Shin HK; Kim MS; Lee JK; Lee SS; Ji YH; Kim JI; Jeong JH
Tumori; 2010; 96(5):713-20. PubMed ID: 21302618
[TBL] [Abstract][Full Text] [Related]
15. EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer.
Martini G; Cardone C; Vitiello PP; Belli V; Napolitano S; Troiani T; Ciardiello D; Della Corte CM; Morgillo F; Matrone N; Sforza V; Papaccio G; Desiderio V; Paul MC; Moreno-Viedma V; Normanno N; Rachiglio AM; Tirino V; Maiello E; Latiano TP; Rizzi D; Signoriello G; Sibilia M; Ciardiello F; Martinelli E
Mol Cancer Ther; 2019 Apr; 18(4):845-855. PubMed ID: 30824612
[TBL] [Abstract][Full Text] [Related]
16. Carfilzomib Promotes the Unfolded Protein Response and Apoptosis in Cetuximab-Resistant Colorectal Cancer.
Zulkifli A; Tan FH; Areeb Z; Stuart SF; Gomez J; Paradiso L; Luwor RB
Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281166
[TBL] [Abstract][Full Text] [Related]
17. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer.
Zalba S; Contreras AM; Haeri A; Ten Hagen TL; Navarro I; Koning G; Garrido MJ
J Control Release; 2015 Jul; 210():26-38. PubMed ID: 25998052
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor-targeted therapy in colorectal cancer.
Xu W; Jing H; Zhang F
Front Biosci (Landmark Ed); 2016 Jan; 21(2):410-8. PubMed ID: 26709782
[TBL] [Abstract][Full Text] [Related]
19. Treatment dilemmas of cetuximab combined with chemotherapy for metastatic colorectal cancer.
Wen F; Li Q
World J Gastroenterol; 2016 Jun; 22(23):5332-41. PubMed ID: 27340349
[TBL] [Abstract][Full Text] [Related]
20. Terminal α2,6-sialylation of epidermal growth factor receptor modulates antibody therapy response of colorectal cancer cells.
Rodrigues JG; Duarte HO; Gomes C; Balmaña M; Martins ÁM; Hensbergen PJ; de Ru AH; Lima J; Albergaria A; van Veelen PA; Wuhrer M; Gomes J; Reis CA
Cell Oncol (Dordr); 2021 Aug; 44(4):835-850. PubMed ID: 33847896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
